Zhonghong Pulin Medical Products Co. Ltd. (300981) — Capital Reinvestment Ratio
Zhonghong Pulin Medical Products Co. Ltd. (300981) has a Capital Reinvestment Ratio of 0.66x as of March 2025, meaning it reinvests 1% of its operating cash flow (CN¥10.91 Million) in capital expenditures (CN¥7.24 Million). Check Zhonghong Pulin Medical Products Co. Ltd (300981) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Zhonghong Pulin Medical Products Co. Ltd. Capital Reinvestment Ratio (2013–2024)
This chart tracks Zhonghong Pulin Medical Products Co. Ltd.'s Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Zhonghong Pulin Medical Products Co. Ltd.
Annual Capital Reinvestment Ratio for Zhonghong Pulin Medical Products Co. Ltd. (2013–2024)
Year-by-year Capital Reinvestment Ratio for Zhonghong Pulin Medical Products Co. Ltd. from 2013 to 2024. See 300981 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.58x | CN¥183.91 Million | CN¥107.40 Million | ▼ -20.4% |
| 2023 | 0.73x | CN¥140.68 Million | CN¥103.17 Million | ▼ -62.3% |
| 2022 | 1.95x | CN¥106.71 Million | CN¥207.65 Million | ▲ +378.6% |
| 2021 | 0.41x | CN¥2.36 Billion | CN¥960.56 Million | ▲ +157.5% |
| 2020 | 0.16x | CN¥2.72 Billion | CN¥429.43 Million | ▼ -80.7% |
| 2019 | 0.82x | CN¥184.38 Million | CN¥150.48 Million | ▼ -90.4% |
| 2018 | 8.54x | CN¥23.77 Million | CN¥203.05 Million | ▲ +950.7% |
| 2017 | 0.81x | CN¥96.03 Million | CN¥78.09 Million | ▲ +34.9% |
| 2016 | 0.60x | CN¥102.37 Million | CN¥61.69 Million | ▼ -54.0% |
| 2015 | 1.31x | CN¥92.23 Million | CN¥120.92 Million | ▲ +925.8% |
| 2014 | 0.13x | CN¥133.33 Million | CN¥17.04 Million | ▼ -83.2% |
| 2013 | 0.76x | CN¥13.37 Million | CN¥10.15 Million | — |